Hardy Sara J, Krull Kevin R, Wefel Jeffrey S, Janelsins Michelle
From the University of Rochester Medical Center, Rochester, NY; St. Jude Children's Research Hospital, Memphis, TN; The University of Texas MD Anderson Cancer Center, Houston, TX.
Am Soc Clin Oncol Educ Book. 2018 May 23;38:795-806. doi: 10.1200/EDBK_201179.
Advances in cancer treatments have led to substantially improved survival for patients with cancer. However, many patients experience changes in cognition as a side effect of both cancer and cancer treatment. This occurs with both central nervous system (CNS) tumors and non-CNS tumors and in both children and adults. Studies of patients with non-CNS cancer have shown that cancer-related cognitive impairment (CRCI), which can include changes in memory, executive function, attention, and processing speed, occurs in up to 30% of patients prior to any treatment and in up to 75% of patients during treatment. A subset of patients with non-CNS and CNS cancer appear to be at higher risk for CRCI, so much research has gone into identifying who is vulnerable. Risk factors for CRCI in adults include cognitive reserve, age, genetic factors, and ethnicity; risk factors for children include genetic factors, female sex, younger age at diagnosis, chemotherapy dose, and both dose and field size for radiation. Although the field has made substantial strides in understanding and treating CRCI, more research is still needed to improve outcomes for both pediatric and adult cancer survivors.
癌症治疗的进展已使癌症患者的生存率大幅提高。然而,许多患者会出现认知变化,这是癌症和癌症治疗的副作用。中枢神经系统(CNS)肿瘤和非CNS肿瘤患者以及儿童和成人都会出现这种情况。对非CNS癌症患者的研究表明,癌症相关认知障碍(CRCI),包括记忆力、执行功能、注意力和处理速度的变化,在任何治疗前高达30%的患者中出现,在治疗期间高达75%的患者中出现。一部分非CNS和CNS癌症患者似乎患CRCI的风险更高,因此有很多研究致力于确定哪些人易患此病。成人CRCI的风险因素包括认知储备、年龄、遗传因素和种族;儿童的风险因素包括遗传因素、女性、诊断时年龄较小、化疗剂量以及放疗的剂量和照射野大小。尽管该领域在理解和治疗CRCI方面取得了重大进展,但仍需要更多研究来改善儿童和成人癌症幸存者的治疗效果。